Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study

Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J, Denkert C, Fasching P, Hanusch C, Tesch H, Weber-Lassalle N, Mueller V, Rhiem K, Untch M, Luebbe K, Lederer B, Jackisch C, Nekljudova V, Schmutzler RK, Hahnen E, Loibl S (2018)

Publication Type: Conference contribution

Publication year: 2018

Journal

Annals of Oncology Elsevier

Publisher: OXFORD UNIV PRESS

City/Town: OXFORD

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: Munich DE

DOI: 10.1093/annonc/mdy270.238

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

GBG Forschungs GmbH (German Breast Group) DE Germany (DE) Universität zu Köln DE Germany (DE) Sana Klinikum Offenbach DE Germany (DE) Universitätsklinikum Hamburg-Eppendorf (UKE) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) HELIOS Kliniken DE Germany (DE) Centrum für Hämatologie und Onkologie Bethanien DE Germany (DE) Ruprecht-Karls-Universität Heidelberg DE Germany (DE) Rotkreuzklinikum München DE Germany (DE) Goethe-Universität Frankfurt am Main DE Germany (DE) DIAKOVERE gGmbH (Diakonische Dienste Hannover (DDH)) DE Germany (DE)

How to cite

APA:

Pohl, E., Schneeweiss, A., Hauke, J., Moebus, V., Furlanetto, J., Denkert, C.,... Loibl, S. (2018). Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.

MLA:

Pohl, E., et al. "Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study." Proceedings of the 43rd ESMO Congress (ESMO), Munich OXFORD: OXFORD UNIV PRESS, 2018.

BibTeX: Download